GAT Therapeutics

GAT-Therapeutics is a preclinical-stage biotechnology company based in Leipzig, Germany, specializing in the development of first-in-class small molecule therapies for rare metabolic diseases. The company's primary focus is on addressing hyperammonemia, a life-threatening condition associated with Urea Cycle Disorders (UCD) and Organic Acidurias (OA). Their lead candidate, GAT-001, acts as a pharmacological activator of glutamine synthetase, an enzyme that facilitates the detoxification of ammonia into glutamine. This approach leverages alternative metabolic pathways to bypass genetic defects in the urea cycle, potentially offering a more effective treatment for patients with limited options. Founded as a spin-off from the University of Leipzig, GAT-Therapeutics is supported by investors such as High-Tech Gründerfonds and Technologiegründerfonds Sachsen.